Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Friday.

A number of other equities research analysts have also recently commented on KPTI. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

NASDAQ:KPTI traded up $0.07 during midday trading on Friday, hitting $0.85. The company's stock had a trading volume of 500,278 shares, compared to its average volume of 1,235,709. The firm has a market cap of $105.89 million, a P/E ratio of -0.75 and a beta of 0.16. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The firm's 50 day moving average is $0.83 and its 200-day moving average is $0.89.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the business earned ($0.30) EPS. As a group, analysts forecast that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth $143,000. Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth $167,000. Exchange Traded Concepts LLC boosted its stake in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock worth $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, FMR LLC boosted its stake in Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company's stock worth $307,000 after purchasing an additional 76,510 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).